AG
NPCE icon

Algert Global’s Neuropace NPCE Stock Holding History

Algert Global’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.36M Buy
179,556
+6,630
+4% +$99.5K 0.04% 673
2025
Q4 		$2.67M Buy
172,926
+75,437
+77% +$1.01M 0.04% 631
2025
Q3 		$1M Buy
97,489
+8,939
+10% +$84.3K 0.02% 837
2025
Q2 		$986K Buy
+88,550
New +$1.11M 0.02% 810

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Algert Global's NPCE Position: Q1 2026 in Review

Algert Global increased its Neuropace (NPCE) stake by 3.8% in Q1 2026, buying an estimated $99.5K and bringing the position to 179,556 shares worth $2.36M. The position accounts for 0.04% of the portfolio, ranked #673.

Algert Global first reported a position in NPCE in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.67M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Algert Global held 179,556 shares of Neuropace worth $2.36M as of Q1 2026.
  • Algert Global bought 6,630 Neuropace shares in Q1 2026, an estimated $99.5K.
  • Neuropace made up 0.04% of Algert Global's portfolio in Q1 2026, its #673 holding.
  • Algert Global first reported a position in Neuropace in Q2 2025 and has held it in 4 quarters since.
  • Algert Global's Neuropace position peaked at $2.67M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.